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total number of customers who patronized the pharma-
cies during the study period. The mean respondents’ sat-
isfaction score was 4.24 (SD 0.52) out of a maximum
possible score of 5.0. Most respondents also supported
the suggestion of providing such services on a wider
scale. However, half the respondents indicated that they
were unwilling to pay for the professional services. CON-
CLUSION: The customers interviewed were satisfied
with the pharmaceutical care services provided but their
responses to paying for the services were less positive.
However, due to the limited time and small number of
participants in this project, a definite conclusion cannot
be drawn as to whether similar results would be obtained
if there were greater awareness by the public.
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INTRODUCTION: Sepsis is a pervasive problem world-
wide, and typically affects persons with significant under-
lying diseases, immunosupression, or major trauma. De-
spite recent advances in therapy and intensive care
medicine, mortality rates have remained essentially un-
changed over the past decade. Furthermore, sepsis is
poorly defined, usually incorporating septicemia, SIRS
and severe sepsis. OBJECTIVE: The purpose of this
study was to determine the outcomes and utilization of
hospital and ICU days in patients with severe sepsis.
METHODS: This evaluation was conducted as part of a
prospective, multi-center, cohort study (“Sepsis Longi-
tudinal Epidemiological Clinical Outcomes Tracking”
[SELECT] registry) in 398 patients with severe sepsis of
presumed infectious origin recruited through 45 ICU
units across the US. For each ICU admission, patient de-
mographic, ICU length of stay (LOS), hospital LOS and
hospital discharge status (dead or alive) was collected. In
addition, data concerning source of infection, comorbidi-
ties and treatments were also collected. RESULTS: In pa-
tients with severe sepsis, the most common comorbidities
were CVD (38%), respiratory failure (36%) and diabetes
(26%), and the majority were admitted from home
(73%). The most common sources of infection were pul-
monary (44%) and abdominal (23%). Overall mortality
in patients with severe sepsis was 42%. ICU survivors
had significantly longer mean hospital LOS (29 vs. 18
days, P  0.01) and ICU LOS (18 vs. 13 days, P  0.01)
compared to non-survivors. Both groups received similar
treatment. CONCLUSION: Based on these observations,
severe sepsis of presumed infectious origin is associated
with a high mortality rate and significant utilization of
hospital resources.
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THE BURDEN OF RESPIRATORY SYNCTIAL 
VIRUS (RSV) HOSPITALIZATIONS IN THE US
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OBJECTIVES: To quantify the burden to the US of RSV
associated hospitalizations using a new (October, 1996)
ICD-9 code for RSV bronchiolitis and two established
RSV codes. METHODS: We conducted a retrospective
analysis of two recent federal databases. The 1997 Na-
tional Hospital Discharge Survey (NHDS) was used to
identify the number of discharges among children under
age 5 with a primary diagnosis of RSV bronchiolitis
(ICD-9 466.11); RSV pneumonia (ICD 480.1) and RSV
(ICD-9 079.6); patient demographics; length of stay
(ALOS); and expected payment source. NHDS formulas
were used to estimate standard errors, normal distribu-
tions were assumed for the calculation of 95% CIs. Mean
charges were generated from the 1996 HCUP-3 NIS and
inflated to 1997 dollars using the Medical Care compo-
nent of the CPI (1.028). RESULTS: In 1997 an estimated
110,000 RSV-associated discharges occurred among chil-
dren under age five. RSV-bronchiolitis accounted for
84% [95% CI, 71%–97%] of RSV discharges; while
RSV pneumonia accounted for 15% [95% CI, 1%–
19%]. ALOS for RSV bronchiolitis was 3.5 days [95%
CI, 3.0–4.0]; 4.3 days [95% CI, 3.2–5.4] for RSV pneu-
monia; and 2.8 [95% CI, 0.3–5.2] for RSV. Mean hospi-
tal charges were $9572 for infants six months and
younger and $9056 for those under age one. 81%
[95%CI, 68%–94%] of children discharged with RSV
were under age one. CONCLUSIONS: Previous studies
may have underestimated the burden of RSV. Estimated
total 1997 hospital charges for RSV in children under age
5 were over $750 million with 75% ($580 million) for
RSV bronchiolitis. Medicaid insured 50% and private in-
surers covered 39% of these discharges. The actual burden
may be larger since RSV infections may be undercoded
and this analysis was restricted to primary diagnoses.
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Even though it is widely recognised that influenza is a se-
rious disease that causes significant consequences in
